IL-1 Receptor Deficiency Slows Progression to Diabetes in the NOD Mouse
- Helen E. Thomas1,
- Windy Irawaty1,
- Rima Darwiche1,
- Thomas C. Brodnicki2,
- Pere Santamaria3,
- Janette Allison4 and
- Thomas W.H. Kay1
- 1St. Vincent’s Institute of Medical Research, Fitzroy, Australia
- 2Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
- 3Department of Microbiology and Infectious Diseases and Julia McFarlane Diabetes Research Centre, Faculty of Medicine, University of Calgary, Alberta, Canada
- 4Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia
- Address correspondence and reprint requests to Dr. Thomas W.H. Kay, St. Vincent’s Institute of Medical Research, 41 Victoria Parade, Fitzroy, VIC, 3065 Australia. E-mail: kay{at}medstv.unimelb.edu.au
Abstract
Proinflammatory cytokines are believed to be important in pancreatic β-cell destruction in the development of type 1 diabetes. They act by upregulation of genes including Fas and inducible nitric oxide synthase (iNOS), which have both been shown to lead to β-cell death in vitro. We used mice deficient in the interleukin (IL)-1 receptor (IL-1R) to assess the contribution of IL-1 to different models of diabetes. IL-1R-deficient islets were protected from the damaging effects of tumor necrosis factor (TNF) and interferon (IFN)-γ in vitro, and β-cell expression of iNOS was reduced, suggesting that IL-1 mediates the induction of iNOS by TNF and IFN-γ. IL-1 action was not required for induction of class I major histocompatibility complex or Fas by TNF and IFN-γ. IL-1R-deficient nonobese diabetic (NOD) mice developed diabetes significantly slower than wild-type mice. IL-1R deficiency did not affect diabetes in 8.3 TCR transgenic NOD mice but prolonged the time to diabetes in BDC2.5 TCR transgenic NOD mice. We conclude that IL-1R deficiency slows progression to diabetes in NOD mice but on its own does not prevent diabetes.
- HRP, horseradish peroxidase
- IFN, interferon
- IL, interleukin
- IL-1R, IL-1 receptor
- IL-1Ra, IL-1R antagonist
- iNOS, inducible nitric oxide synthase
- LPS, lipopolysaccharide
- MHC, major histocompatibility complex
- NO, nitric oxide
- TNF, tumor necrosis factor
Footnotes
-
- Accepted October 13, 2003.
- Received March 16, 2003.
- DIABETES











